SANDOSTATIN LAR is a prescription drug with octreotide as its main ingredient. It is used to treat some endocrine diseases, such as acromegaly and carcinoid syndrome. Currently, SANDOSTATIN LAR has been launched in China. This article provides a detailed description of its indications, dosage, side effects, contraindications, and clinical efficacy.
(I) Indications
SANDOSTATIN LAR 10mg, 20mg, and 30mg are suitable for patients who are initially effective and tolerant to SANDOSTATIN LAR.
1. Acromegaly
Patients with acromegaly who have an inadequate response to surgery and/or radiotherapy, or patients who cannot choose surgery and/or long-term maintenance therapy. The goal of acromegaly treatment is to reduce growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels to normal levels.
2. Carcinoid
Long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid.
3. VIPoma
Long-term treatment of massive watery diarrhea associated with VIPoma.
4. Important Limitations of Use
In patients with carcinoid syndrome and vipoma, the effects of Sanlon on tumor size, growth rate, and development of metastases are uncertain.
(II) Dosage and Administration
1. Instructions for Use
(1) Sanlon should be administered by trained medical personnel, and it is important to strictly follow the instructions on the package. Sanlon needs to be used immediately after mixing.
(2) Do not inject diluent directly without preparing a suspension.
(3) The recommended needle size for Sanlon is a 1½” 19-gauge safety injection needle (provided in the drug package). For patients with greater skin-to-muscle depth, a 2-inch 19-gauge needle (not provided) can be used.
(4) Sanlon should be injected intramuscularly in the gluteal area every 4 weeks. It is not recommended to administer Sanlon more than 4 weeks apart.
(5) The injection site should be rotated on a planned basis to avoid irritation. Injections into the deltoid muscle should be avoided because injection site discomfort is significant when injecting in this area.
(6) It should not be given intravenously Intravenous injection or subcutaneous injection.
(III) Applicable population
Adults. Children, breastfeeding women and the elderly and infirm should use it under the guidance of a doctor.
(IV) Side effects
Common side effects (incidence ≥ 20%) are as follows:
1. Acromegaly: diarrhea, cholelithiasis, abdominal pain, flatulence.
2. Carcinoid syndrome: back pain, fatigue, headache, abdominal pain, nausea, dizziness.
(VI) Precautions
1. Cholelithiasis and its complications
Sanlong may inhibit gallbladder contraction and reduce bile secretion, which may Causes gallbladder abnormality or congestion. Complications caused by cholelithiasis (gallstones), including cholecystitis, cholangitis, pancreatitis, etc. Patients should be monitored regularly. If complications of cholelithiasis are suspected, Sanlong needs to be discontinued and treated appropriately.
2. Hyperglycemia and hypoglycemia
Octreotide changes the balance between counter-regulatory hormones such as insulin, glucagon, and growth hormone (GH), which may lead to hypoglycemia or hyperglycemia. When starting treatment with Sanlong or changing the dose, blood glucose levels should be monitored and diabetes treatment should be adjusted accordingly.
3. Abnormal thyroid function
Octreotide inhibits the secretion of thyroid stimulating hormone (TSH), which may lead to hypothyroidism. It is recommended to regularly evaluate thyroid function during Sanlong treatment.
(IX) Storage conditions
For long-term storage of Sanlong, the drug vial should be stored in a refrigerator at 2-8℃ and avoid freezing and light. About 24 hours before injection, this product should be placed at room temperature. The prepared solution of this product should be used immediately.
[Warm Tips]: The instructions for some products are frequently changed, please refer to the actual product.
